Association between antipsychotics and cardiovascular adverse events: A systematic review
Ana Amancio Santos Da Silva1, Marina Viegas Moura Rezende Ribeiro1, Célio Fernando de Sousa-Rodrigues2
1MSc in Health Sciences, Universidade Federal de Alagoas (Ufal), Maceió, AL, Brazil.
Objective::
Determine whether there is an association between the risk of cardiovascular adverse events and the use of antipsychotic agents.
Method::
Analysis of original articles retrieved from the following databases: LILACS, PubMed, Cochrane Controlled Trials Clinical Data Bank (CENTRAL) and PsycINFO, without language restriction, dated until November 2015. After screening of 2,812 studies, three cohort original articles were selected for quality analysis.
Results::
403,083 patients with schizophrenia and 119,015 participants in the control group data were analyzed. The occurrence of cardiovascular events observed in the articles was: 63.5% (article 1), 13.1% (article 2) and 24.95% (article 3) in the group of treated schizophrenic patients, and 46.2%, 86.9% and 24.9%, respectively, in the control groups.
Conclusion::
Clinical heterogeneity among the studies led to a provisional response and made it impossible to perform the meta-analysis, although the articles demonstrate an association between cardiovascular adverse events and the use of antipsychotics. More quality clinical trials are needed to support this evidence.
More Related Videos
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Typical and Atypical Agents
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Antidepressant Drugs: MAOIs and Other Agents
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...


